HIV-2-infected individuals with undetectable plasma viremia carry replication-competent virus in peripheral blood lymphocytes

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 3, 2004, Pages 777-782

  Blaak, Hetty ^a   Boers, Patrick H M ^a   Schutten, Martin ^a   Van Der Endeñ, Marchina E ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aviremic HIV 2 infection; HIV 2; Infectious cellular load; Peripheral blood mononuclear cells; Plasma RNA load; Replication competent virus

Indexed keywords

CD4 ANTIGEN;

ARTICLE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REPLICATION COMPETENT VIRUS; T LYMPHOCYTE; VIREMIA; VIRUS CULTURE; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION;

CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HIV-2; HUMANS; LYMPHOCYTES; NETHERLANDS; RNA, VIRAL; VIREMIA; VIRUS REPLICATION;

EID: 3042775350     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200407010-00003     Document Type: Article

References (34)

1. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265:1587-1590.
2. Jaffar S, Wilkins A, Ngom PT, et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:327-332.
3. Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis. 2002;185:905-914.
4. Berry N, Ariyoshi K, Jaffar S, et al. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1998;1:457-468.
5. Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis. 1999;180:1116-1121.
6. Damond F, Gueudin M, Pueyo S, et al. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol. 2002;40:3654-3659.
7. De Cock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. JAMA. 1993;270:2083-2086.
8. Albert J, Naucler A, Bottiger B, et al. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS. 1990;4:291-295.
9. Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS. 1993;7:1411-1417.
10. van der Ende ME, Schutten M, Ly TD, et al. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS. 1996;10:1649-1655.
11. Schutten M, van den Hoogen B, van der Ende ME, et al. Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods. 2000;88:81-87.
12. Strijbosch LW, Does RJ, Buurman WA. Computer aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput. 1988;23:279-290.
13. Roda Husman AM, van Rij RP, Blaak H, et al. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. J Infect Dis. 1999;180:1106-1115.
14. Blaak H, Brouwer M, Ran LJ, et al. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis. 1998;177:600-610.
15. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989;321:1621-1625.
16. Paxton WB, Coombs RW, McElrath MJ, et al. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1997;175:247-254.
17. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998;92:3105-3114.
18. Can Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332:201-208.
19. van Rij RP, van Praag RM, Prins JM, et al. Persistence of viral HLA-DR-CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. Antivir Ther. 2002;7:37-41.
20. van Rij RP, Visser JA, van Praag RM, et al. Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J Virol. 2002;76:3054-3058.
21. Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869-8873.
22. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
23. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
24. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. NEnglJMed. 1999;340:1605-1613.
25. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
26. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193-13197.
27. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.
28. Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science. 2002;298:995-1000.
29. Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology. 1989;66:628-630.
30. Koot M, 't Wout AB, Kootstra NA, et al. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis. 1996;173:349-354.
31. Connor RI, Mohri H, Cao Y, et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993;67:1772-1777.
32. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
33. Popper SJ, Sarr AD, Gueye-Ndiaye A, et al. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol. 2000;74:1554-1557.
34. Saha K, Bentsman G, Chess L, et al. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol. 1998;72:876-881.